A drug-resistant duo

Hugo Lavoie and Marc Therrien ()
Additional contact information
Hugo Lavoie: Hugo Lavoie and Marc Therrien are at the Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3C 3J7, Canada.
Marc Therrien: Hugo Lavoie and Marc Therrien are at the Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec H3C 3J7, Canada.

Nature, 2011, vol. 480, issue 7377, 329-330

Abstract: The efficacy of the anticancer drug vemurafenib, which is used to treat metastatic melanoma, is plagued by acquired resistance. A picture of how such resistance develops is emerging. See Letter p.387

Date: 2011
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/480329a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:480:y:2011:i:7377:d:10.1038_480329a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/480329a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().